Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Pfizer Posts Mixed Results from Chinese Lyrica Studies

August 13, 2014 11:08 am | News | Comments

Pfizer Inc. announced top-line results from two placebo-controlled studies conducted in China with Lyrica (pregabalin) in patients with postherpetic neuralgia (pain after shingles or PHN) and painful diabetic peripheral neuropathy (pDPN), respectively. Read more...

TOPICS:

Meta-Analysis Approach May Affect Conclusion

August 13, 2014 11:02 am | News | Comments

Depending on the analysis strategy used, estimating treatment outcomes in meta-analyses may differ and may result in major alterations in the conclusions derived from the analysis, according to a study in the August 13 issue of JAMA. Read more...

TOPICS:

UN: OK to Use Untested Ebola Drugs in Outbreak

August 13, 2014 10:57 am | by Maria Cheng, Ciaran Giles, Associated Press | News | Comments

The World Health Organization declared it's ethical to use untested drugs and vaccines in the ongoing Ebola outbreak in West Africa, although the tiny supply of one experimental treatment has been depleted and it could be many months until more is available. Read more...

TOPICS:
Advertisement

MJFF Highlights Promising Parkinson's Disease Drug Research

August 12, 2014 3:21 pm | News | Comments

Research projects from five groups active in Parkinson's research comprise the 2014 first half (1H 2014) of The Michael J. Fox Foundation for Parkinson's Research (MJFF) Partnering Program. Read more...                

TOPICS:

Epigenetic Cancer Cell Markers Could Improve Treatment

August 12, 2014 3:05 pm | News | Comments

Scientists have known for decades that cancer can be caused by genetic mutations, but more recently they have discovered that chemical modifications of a gene can also contribute to cancer. These alterations, known as epigenetic modifications, control whether a gene is turned on or off. Now, a team engineers has developed a fast, reliable method to detect this type of modification. Read more...

TOPICS:

Long-Sought Drug Candidate Can Halt Tumor Growth

August 12, 2014 2:50 pm | News | Comments

It’s a trick any cat burglar knows: to open a locked door, slide a credit card past the latch. Scientists tried a similar strategy when they attempted to disrupt the function of MYC, a cancer regulator thought to be “undruggable." Read more...   

TOPICS:

Clinical Trial Evaluates Safety of Stem Cell Transplantation in Spine

August 12, 2014 2:41 pm | Videos | Comments

Researchers have launched a clinical trial to investigate the safety of neural stem cell transplantation in patients with chronic spinal cord injuries. This Phase 1 clinical trial is recruiting eight patients for the five-year study. Read more...

TOPICS:

Ebola: Questions, Answers About Unproven Drug

August 12, 2014 2:25 pm | by Lauran Neergaard, AP Medical Writer | News | Comments

An experimental Ebola drug has been used to treat two American aid workers and a Spanish missionary priest, and the Liberian government said that it will receive doses of the drug to treat two doctors in the country. Read more...       

TOPICS:
Advertisement

Cortendo Enrolls First Patient into Cushing’s Study

August 12, 2014 11:43 am | News | Comments

Cortendo AB announced that the first patient has been enrolled into the Phase 3 SONICS trial, i.e., “Study of NormoCort in Cushing’s Syndrome,” after successfully completing its European Investigator meeting supporting SONICS. Read more...

TOPICS:

Prosensa, CureDuchenne Strengthen Collaboration

August 12, 2014 11:38 am | News | Comments

Prosensa Holding N.V. announced that an affiliate of CureDuchenne will provide Prosensa with up to €5 million by means of convertible promissory notes to support the company and accelerate the development and patient access of much needed DMD therapies. Read more...

TOPICS:

Sanofi Launches Generic Eloxatin

August 12, 2014 11:31 am | News | Comments

Sanofi US announced that it has launched an authorized generic version of Eloxatin (oxaliplatin injection) through Winthrop US, the company's generics division. Sanofi's authorized generic version is the same formulation as the original drug, Eloxatin, for which the company holds the original patent. Read more...

TOPICS:

23andMe, Pfizer Collaborate on Genetics of IBD

August 12, 2014 11:24 am | News | Comments

23andMe announced an agreement with Pfizer Inc. in which the companies will aim to enroll 10,000 people with Inflammatory Bowel Disease (IBD) in a research initiative designed to explore the genetic factors associated with the onset, progression, severity and response to treatments for IBD. Read more...

TOPICS:

Bioengineers Create 3-D Brain-Like Tissue

August 12, 2014 11:17 am | News | Comments

Bioengineers have created three-dimensional brain-like tissue that functions like and has structural features similar to tissue in the rat brain, can be kept alive in the lab for more than two months and could provide a superior model for studying normal brain function as well as injury and disease. Read more...

TOPICS:

Liberian Doctors to Get Experimental Ebola Drug

August 12, 2014 11:02 am | by Jonathan Paye-Layleh, Maria Cheng, Associated Press | News | Comments

Liberia announced Monday that it would soon receive doses of an experimental Ebola drug and give it to two sick doctors, making them the first Africans to receive some of the scarce treatment in a spiraling outbreak, which has claimed the lives of 1,013 people in West Africa. Read more...

TOPICS:

Intercept Liver Drug Excels in Trial

August 12, 2014 9:21 am | News | Comments

Shares of Intercept Pharmaceuticals Inc. soared in premarket trading Tuesday, a day after the drug developer said its most advanced candidate performed better than a placebo in a mid-stage study of patients with a form of chronic liver disease. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading